Hyperfine (NASDAQ:HYPR – Get Free Report) is anticipated to post its Q3 2025 results after the market closes on Thursday, November 13th. Analysts expect Hyperfine to post earnings of ($0.10) per share and revenue of $3.5070 million for the quarter. Investors can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Thursday, November 13, 2025 at 4:30 PM ET.
Hyperfine (NASDAQ:HYPR – Get Free Report) last announced its quarterly earnings results on Wednesday, August 13th. The company reported ($0.12) earnings per share for the quarter, meeting the consensus estimate of ($0.12). Hyperfine had a negative net margin of 364.54% and a negative return on equity of 84.82%. The company had revenue of $2.70 million during the quarter, compared to the consensus estimate of $3.00 million. On average, analysts expect Hyperfine to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Hyperfine Stock Up 6.8%
Shares of NASDAQ HYPR opened at $1.10 on Wednesday. The firm has a market cap of $86.44 million, a P/E ratio of -2.12 and a beta of 1.08. Hyperfine has a twelve month low of $0.53 and a twelve month high of $2.22. The company has a 50 day moving average of $1.39 and a 200 day moving average of $1.06.
Wall Street Analysts Forecast Growth
Read Our Latest Stock Analysis on Hyperfine
Institutional Inflows and Outflows
An institutional investor recently raised its position in Hyperfine stock. Vanguard Group Inc. grew its stake in shares of Hyperfine, Inc. (NASDAQ:HYPR – Free Report) by 5.7% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,511,972 shares of the company’s stock after buying an additional 190,136 shares during the period. Vanguard Group Inc. owned 4.47% of Hyperfine worth $5,092,000 at the end of the most recent reporting period. Institutional investors own 15.03% of the company’s stock.
About Hyperfine
Hyperfine, Inc, a medical device company, provides magnetic resonance imaging (MRI) products in the United States. The company offers Swoop Portable MR imaging system, which offers portable brain neuroimaging; and support and technical assistance services. It serves ICU, comprehensive, and primary stroke accredited facilities through direct sales and distributors.
See Also
- Five stocks we like better than Hyperfine
- 3 Ways To Invest In Coffee, Other Than Drinking It
- CoreWeave’s Guidance Cut: A Buying Opportunity in Disguise?
- 10 Best Airline Stocks to Buy
- Strategy Shares Plunge as Bitcoin Retreats—More Pain Ahead?
- What Does a Stock Split Mean?
- BigBear.ai Stock Is Range-Bound—Wall Street Isn’t Buying the Hype
Receive News & Ratings for Hyperfine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hyperfine and related companies with MarketBeat.com's FREE daily email newsletter.
